Amidst a federal investigation, Granuflo lawsuits are on the rise among dialysis patients. The dry acid neutralizer widely used within dialysis centers nationwide is said to cause potentially life threatening side effects. From the supplier Fresenius’s own clinics to many private treatment centers patients were continuously put at risk without proper notification of the dangerous findings out of their very own office. Due to their accused negligence, knowledgeable attorneys are assisting patients with initiating Granuflo lawsuits nationwide.
Along with Naturalyte, another product out of Fresenius, this acid concentrate power includes a component that the body utilizes and converts to bicarbonate, an alkaline substance. Ultimately the product is used to neutralize any present acid in the patient’s blood. Bicarbonate is frequently an aggressive ingredient towards other drugs used during kidney hemodialysis. Fresnius’ product has an increased amount which can put patients in danger of conditions such as alkalosis, cardiac arrest, and cardiovascular death.
In late 2011 the company distributed a memo internally to the doctors within their own dialysis treatment locations to inform them of the dangerous effects the product can have if not made use of properly. When combined with an additional prescription of bicarbonate the heightened quantity can result in a possible overdose. Despite this acknowledgement to their own practices, notification was not disbursed to privately owned centers. Eventually, in March of 2012 the internal notice was leaked resulting in an investigation and Class I recall by the Food and Drug Administration (FDA). While they provide dialysis for roughly a third of the 400,000 Americans receiving such treatment, the FDA is determining whether they infringed upon federal regulations by not notifying all patients, no matter what center they attend.
Approximately 125,000 dialysis patients go to centers not under Fresenius ownership, therefore a substantial number of customers were placed in danger. With about a 6% chance of suffering a heart attack with the elevated amount of bicarbonate, it comes as no surprise that a large number of victims have filed Granuflo lawsuits against the supplier.
As of January of 2013 over 30 legal cases accusing Fresnius of not issuing a warning to all using patients were pending at the federal court level. It has not yet been determined whether or not a class action suit will be formed, but individual cases can be pursued in the meantime. Due to the variation in side effects between patients any large scale litigation will most likely be a multidistrict case. A class action case would apply only in the case that multiple customers can be grouped by comparable damages being sought. Individual Granuflo lawsuits can be filed and continued despite the delay in mass tort action being decided. Working with an attorney knowledgeable on the subject can ensure a proper and thorough case is formed. If and when a class action or multidistrict litigation is developed, single defendant cases will not be affected. At that point an attorney can advise their client as to the advantages and disadvantages of choosing involvement within that mass litigation.
Fresnius’ s response to the growing number of Granuflo lawsuits is one of loyalty to their product. Their belief is that proper procedures were followed and any litigation against them is erroneous and “without merit”. Despite receiving and adequately responding to a subpoena from the District of Massachusetts, the company plans to stand strong against all allegations of wrongdoing.